A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled and Parallel Group 48-Week Study to Evaluate the Efficacy and Safety of ALT-801 in the Treatment of Obesity (MOMENTUM Trial)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Sep 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 Sep 2024 According to an Altimmune Media Release, data from this study will be presented at the 60th Annual Meeting of the European Association for the Study of Diabetes in Madrid, Spain,September 10, 2024.
08 Aug 2024 According to an Altimmune Media Release, the company announced that On June 22 and 23, the Company presented data from its Phase 2 MOMENTUM obesity trial at the American Diabetes Associations (ADA) 84th Annual Scientific Sessions
23 Jun 2024 According to an Altimmune Media Release, results form this trial were presented at the American Diabetes Association's (ADA) 84th Scientific Sessions.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com